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ABSTRACT: Osteoarthritis is a chronic painful condition affecting larger joints; most 
commonly knee joint. Pharmacological control of pain is the mainstay of management of 
osteoarthritis. Many patientsfail to achieve satisfactory reduction in pain with one of the 
most commonly prescribed drugs, diclofenac sodium, even after maximum daily allowed 
doses. Lornoxicam is a newer molecule in the Indian market promising better pain relief in 
context of low back pain and post knee replacement surgery pain as compared to standard 
therapies. As per profile of lornoxicam, if it is better than diclofenac sodium then it will be 
helpful in managing the patients of osteoarthritis more effectively. Till date no comparative 
clinical trial has been done to compare these two drugs for the management of 
osteoarthritis knee. So, to evaluate the same we carried out this study to compare safety, 
efficacy and cost effectiveness of lornoxicam and diclofenac sodium in relieving pain in 
patients of osteoarthritis knee. This study is a randomized, open labeled, controlled clinical 
trial having 40 newly diagnosed patients with osteoarthritis knee. After random allocation 
into two groups i.e. group D and group L (each having 20 patients); group D received 
diclofenac sodium 50 mg 12 hourly and group L received lornoxicam 4 mg 8 hourly for a 
period of 3 months. All patients were assessed with visual analogue scale and 100 meter 
walking test before starting of therapy, at 15 days and at 1, 2 and 3 months of therapy. 
Adverse drug reactions and cost of therapy was monitored during the study period. Mean 
decrease in visual analogue scale and time of 100 meter walking test was statistically 
significant in lornoxicam group as compared to diclofenac sodium. Gastric irritation was 
reported in one patient from group L and two patients from group D. Lornoxicam 
significantly relieves pain of osteoarthritis knee than diclofenac sodium without adversely 
affecting the tolerability to the patients. 
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INTRODUCTION
ᴪ 
 
Osteoarthritis is a chronic degenerative condition 
affecting joints including articular cartilage and 
subchondral bone. Symptoms may include joint 
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pain, tenderness, stiffness and locking of affected 
joint and sometimes joint cavity effusion. In 
majority, large joints of human body are affected 
more than smaller joints
1
. Among these larger 
joints, knee joint is most commonly affected. 
Osteoarthritis affects women more than men and 
prevalence increases with age
2
. Osteoarthritis  of 
knee is one of  five  leading  causes of  disability  
among  non-institutionalized adults and also is a 
leading  cause  of  impaired mobility  in elderly
3
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Approximately 25% of persons of 55 years of age 
or older have had knee pain on most days in a 
month in the year 2000
4
. 
Apart from permanent cure in the form of costly 
joint replacement surgery; management of 
osteoarthritis knee generally involves a 
combination of exercise, lifestyle modification and 
analgesics. Diclofenac sodium and lornoxicam
5
 
both are acid derivative analgesics which gets 
accumulated in the inflamed tissue like joints 
affected by osteoarthritis
6
. Diclofenac sodium is 
one of the most commonly prescribed drugs for the 
osteoarthritis knee. But, observational studies have 
raised the possibility of a cardiovascular risk from 
chronic therapy with diclofenac sodium
7
.  
Lornoxicam has come in Indian market since last 
few years. It is found to be a better alternative for 
management of conditions like post lumbar 
puncture pain
8, post tooth extraction pain
9 but less 
information is available regarding its safety, 
efficacy and cost effectiveness in osteoarthritis 
knee. As per the profile, if lornoxicam is really 
more beneficial than diclofenac sodium then it will 
be helpful in managing the patients of osteoarthritis 
more effectively. To confirm the same we planned 
this study. 
 
METHODOLOGY 
 
With prior approval of institutional review board of 
Government Medical College, Bhavnagar, Gujarat 
(India); the study was carried out at Department of 
Orthopedics, Sir Takhtasinhji General Hospital and 
Government Medical College, Bhavnagar. Study 
was registered on www.clinicaltrials.gov 
(NCT01055470). Study was conducted as per 
Declaration of Helsinki and ICH-GCP. Study was 
randomized, open labeled, parallel group 
comparative clinical trial with 3 months duration in 
addition of one week run-in period. The aim of the 
run-in period was to make the groups comparable 
with regard to the treatment strategy at the point of 
randomization. Tablet diclofenac sodium (50 mg), 
Tablet lornoxicam (4 mg), visual analogue scale, 
patient information sheet, consent form (in 
vernacular language) were used for study. As this 
was a pilot study to compare the effectiveness of 
two medications in the management of 
osteoarthritis knee, no formal sample size 
calculation was performed. 
Patients aged between 25 to 65 yrs of either gender 
suffering from osteoarthritis of knee diagnosed 
according to criteria given by American College of 
Rheumatology
10 were explained about the study. 40 
patients who gave written informed consent were 
assigned randomly (using Random Number Table) 
into two groups i.e. group D (diclofenac sodium 
group) and group L (lornoxicam group) of 20 
patients each with allocation ratio ofone. 
Patients having any other systemic illness, pregnant 
and lactating women, patients taking other drugs 
like lithium
11
, digoxin, methotrexate, 
anticoagulants, antidiabetic drugs namely 
sulfonylureas and biguanides, diuretics, 
cyclosporine, quinolone antibiotics, having history 
of hypersensitivity to non steroidal anti-
inflammatory drugs and patient who consumed any 
analgesic in last 1 month were excluded from the 
study. 
For 3 months, patients of group D received 
diclofenac sodium 50 mg (Generic Supply) every  
12 hourly and group L received lornoxicam  4 mg  
(Tab. Fulactive, Ranbaxy Pharmaceuticals, India) 
every 8 hourly. Medicines were given orally and 
the patients were advised to take them after meals. 
Patients were assessed with the help of visual 
analogue scale
12
 and 100 meters walking test. 
Visual analogue scale is a pain scale in which pain 
of osteoarthritis of knee is recorded in gradations 
from 0 to 4. Zero means no pain and 4 means 
severe pain. In 100 meters walking test, time taken 
by the patient to walk distance of 100 meters is 
recorded in seconds.  Visual analogue scale was 
recorded immediately after completing 100 meters 
walking test. The outcome was difference in 
reduction in the visual analogue scale reading as 
well as in time of 100 meters walking test in both 
groups. Visual analogue scale and 100 meters 
walking test were checked by same person at every 
time to eliminate observer bias. 
Observations of visual analogue scale and 100 
meters walking test were compared at the end of 15 
days, and at the end of 1, 2 and 3 months of 
therapy. For visual analogue scale, groups were 
compared to each other by Mann Whitney Rank 
sum test and for 100 meters walking test by 
unpaired “t” test. Intra-group results of visual 
analogue scale test were analyzed by Friedman’s 
test followed by Dunn’s multiple comparison test. 
Intra-group results of 100 meters walking test were 
analyzed by repeated measure ANOVA followed 
by Tuckey Crammer multiple comparison test. P < 
0.05 was considered as statistically significant. 
During study period, side effects and cost of drugs 
were monitored in both groups. Statistical analysis 
was carried out using Graphpad Instat 3 (Demo 
version). 
Direct medical costs (cost of interventional drug) 
and clinical outcome of patients managed with the 
two study groups were estimated in order to 
identify the differences among them and to obtain 
an incremental cost-effectiveness ratio (ICER), 
integrating the values obtained from the study to 
the following formula: 
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ICER  
Total Cost                Total Cost                    
Effictiveness                Effictiveness                    
 
 
Thus, in this study, ICER was obtained by dividing 
net cost difference with the difference in net 
effectiveness for two alternative treatments 
(Lornoxicam vs. Diclofenac Sodium). 
Effectiveness measure used for this evaluation was 
the number of patients with effective pain control 
(visual analogue scale score = 0 at 3 month 
therapy) without any adverse event per each study 
group. 
 
RESULTS 
 
Demographic characteristics of both groups were 
comparable to each other; with preponderance of 
female patients in both, and mean age of patient 
was 49.6 years. No patient dropped out from the 
study. Overall pain reduction, assessed by the 
visual analogue scale, achieved in both groups 
continued to be same till 1 month treatment. But 
thereafter there was statistically significant 
difference between reduction of pain assessed by 
visual analogue scale (68.09 % reduction in group 
L as compared to 45.45 % reduction in group D at 
2 months; P<0.05 and 80.89% reduction in group L 
as compared to 45.45 % reduction in group D at 3 
months; P<0.001). Mean pain score of group L was 
less than results of group D after 2 and 3 months of 
treatment (Table 1). 
In both groups, pain reduction assessed by the 100 
meters walking test continued to be same till 2 
months treatment. But at the end of 3 months there 
was statistically significant difference between both 
groups (20.11% reduction in time for group L as 
compared to 13.11 % reduction in time for group D 
at 3 months; P<0.05). Mean time of 100 meters 
walking test for group L was less than that of group 
D. Also at 3 months, group L shows significant 
difference compared to baseline as well as at 15 
days, 1 month and 2 month duration of treatment 
(P<0.001). (Table 2) 
ICER was found to be 0.949 which was obtained 
by dividing net cost difference with the difference 
in net effectiveness for two alternative treatments 
drugs (lornoxicam vs. diclofenac sodium). 
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DISCUSSION 
 
The main aim of this study was to compare 
analgesic effectiveness of lornoxicam and 
diclofenac sodium in patients of osteoarthritis of 
knee. Our study showed that lornoxicam was more 
effective than diclofenac. These results are in 
accordance with previous clinical trials like a 
randomized, double-blind, placebo controlled trial 
involving 46 patients in each group which 
concluded that lornoxicam administration in total 
knee replacement was associated with decreased 
morphine consumption for postoperative analgesia 
and fewer side effects
13.   Lorenz et al reported that 
intravenously administered lornoxicam typically 
suppressed pain-induced brain activation in all 
regions except the hippocampus in a Functional 
Magnetic Resonance Imaging (fMRI) compatible 
pain model mimicking surgical pain at anterior 
margin of the right tibia
14. Yakhno et al found that 
lornoxicam administered as a quick-release 
formulation was non-inferior to the equivalent 
formulation of diclofenac potassium in terms of 
onset of pain relief and more effective on most of 
the major standard efficacy outcomes in 220 
patients having low back pain
15. 
Polymorphonuclear cell invasion into the joint 
cavity is one of the important factors in acute 
inflammatory diseases like osteoarthritis of knee. 
This process depends on the augmentation of 
several biological factors with chemotactic activity 
and probably interleukin-8 (IL-8) at the site of 
inflammation
16
. Accumulation of 
polymorphonuclear cells also leads to release of 
mediators which further enhance the inflammatory 
cascade
16
. 
Effect of the lornoxicam increased over duration of 
therapy (i.e. reduction in pain- 40.43 % at 15 days, 
61.70 % at 1 month, 68.09 % at 2 months and 
80.85 % at 3 months, Table 1).  Probable reason of 
this incremental effect is that lornoxicam inhibits 
human polymorphoneuclear cell migration induced 
by f -myeloperoxidase, IL-8 and substance P
17
 
which are some of the important chemotactic 
mediators of inflammation. As it is clinically 
difficult to study the effect of a drug on articular 
cartilage, it should be confirmed with advanced 
procedures like arthroscopy. 
During the study, no other adverse drug reaction 
except gastric irritation was reported in one patient 
from group L and two patients from group D. This 
was managed by Cap. Omeprazole 20 mg 12 
hourly for 5 days and these patients showed their 
willingness to continue in study and successfully 
completed full duration of study. None of the 
patients developed cardiovascular adverse reactions 
like edema or increase in blood pressure. 
Drug with the highest per day therapy cost was 
lornoxicam (Rs. 11.17) and difference in cost was 
significant with the use of diclofenac sodium (Rs. 
1.68). But, as far as effectiveness is concerned, the 
drug with the largest number of patients with 
effective pain control without developing adverse 
events is again lornoxicam. In addition, per 3 
months therapy, treatment of adverse drug 
reactions reported in both groups increased average 
one day therapy cost by Rs. 0.45 in group D and 
Rs. 0.22 in group L in respective patients. When 
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it is observed that lornoxicam is more effective 
than diclofenac sodium with a higher cost. As 
lornoxicam is newer molecule in the market, there 
is scope for its price reduction in future. 
 
CONCLUSION 
 
From above results we can conclude that 
lornoxicam significantly relieves pain of 
osteoarthritis knee more than diclofenac sodium 
without adversely affecting the tolerability to the 
patients. However, as this was a pilot study with 
limited sample size, relative short study duration 
and open-label design, more studies with larger 
sample size, longer duration, and blinding 
techniques are necessary to substantiate our 
observations. 
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